Emavusertib

Emavusertib : Inhibitor of IRAK4

Structure

Information

  • IRAK4
  • Inhibitor
  • up to 5 uM
  • Reviewer recommended concentration: up to 1 µM to limit off-target effect (CLK-family)

In Vitro Validations

Uniprot ID: Q9NWZ3
Target Class: Kinase
Target SubClass: TKL
Potency: IC50
Potency Value: 31.7 nM
Potency Assay: TR-FRET assay using recombinant IRAK4 kinase
PDB ID for probe-target interaction (3D structure): 7C2V
Target aliases:
Interleukin-1 receptor-associated kinase 4, IRAK4, ...

DOI Reference: 10.1021/acsmedchemlett.0c00255

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Potency assay (off target): Evaluated in a broad kinome panel (Eurofins, 329 kinases) at 1 µM and 10 µM. Apart from IRAK4, Emavusertib was also observed to be exhibiting significant activity (≥50% inhibition at 1 μM) in a handful of other kinases such as CLK1, CLK2, CLK4, FLT3, DYRK1A, DYRK1B, TrkA, TrkB, Haspin, and NEK11. Also tested in small panel of kinases at 100 nM and 1 µM, showing some inhibition of FLT3.
I have extra information to add

SERP ratings and comments


SERP+ Ratings

In Cell Rating
In Model Organisms

SERP+ Comments:

The probe is generally well characterized and optimized for in vivo use. At 1 µM four other kinases (FLT3, CLK1, CLK2 and CLK4) are inhibited >90% (target inhibiton at this conectration = 82%). The compound is profiled extensively in model organisms (mouse, rat and dog) and has very good oral bioavailability. The in vivo activity was confirmed in xenograft models. A control compound is missing. At the moment (Mar 2023), it is one of the best tool compounds but care has to be taken regarding possible off-targets. The use of orthogonal probes is highly recommended.

(last updated: 22 Mar 2023 )